Trial of New Alzheimer’s Drug Reports Disappointing Results June 16, 2022 crenezumab +6 failed to prevent early symptoms or slow cognitive decline IFTTT NYT NYT > Business NYTimes The drug the latest setback in the long quest to find effective therapies for the disease. crenezumab failed to prevent early symptoms or slow cognitive decline IFTTT NYT NYT > Business NYTimes The drug the latest setback in the long quest to find effective therapies for the disease.
Three F.D.A. Advisers Resign Over Approval of Alzheimer's Drug June 10, 2021 000 per year +3 a monthly infusion priced at $56 Aduhelm IFTTT NYT NYT > Business NYTimes The drug was approved this week despite weak evidence that it helps patients. 000 per year a monthly infusion priced at $56 Aduhelm IFTTT NYT NYT > Business NYTimes The drug was approved this week despite weak evidence that it helps patients.
Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense June 08, 2021 Aduhelm +6 Despite scant evidence that it works IFTTT is predicted to generate billions of dollars in revenue much of it from Medicare. NYT NYT > Business NYTimes The drug Aduhelm Despite scant evidence that it works IFTTT is predicted to generate billions of dollars in revenue much of it from Medicare. NYT NYT > Business NYTimes The drug
Latest Monoclonal Antibody Treatment Approved for High-Risk Patients May 26, 2021 +3 aims to keep Covid patients out of the hospital. from GlaxoSmithKline and Vir IFTTT NYT NYT > Business NYTimes The drug aims to keep Covid patients out of the hospital. from GlaxoSmithKline and Vir IFTTT NYT NYT > Business NYTimes The drug